MANN FUNG, MD, MBA, MHCM, FACP
Chief Executive Officer
Dr. Mann Fung is the Chief Executive Officer of Tavotek Biotherapeutics. He has nearly 30 years of experience in the Regulatory, Pharmaceutical and Finance Industries including FDA, Big Pharma, and Venture Capital. Prior to joining Tavotek in 2019, Dr. Fung was a Venture Partner at Fidelity Eight Roads Ventures as well as a clinical consultant for BioMotiv Capital. He is currently an Investment Committee member of the Apricot-Sanhe Entrepreneur Fund and a Scientific Advisory Board member of Virogin Biotech and YiSheng Biopharma.
Dr. Fung began his career as a practicing physician before joining the US Food and Drug Administration (FDA) as a Medical Reviewer in the early 1990s. He joined Eli Lilly & Company and started his pharmaceutical career with increasing responsibilities including serving a 5-year international assignment for Eli Lilly as the Medical Director of Lilly Greater China TW Operations, and later as the Head of Oncology and Critical Care Products for Lilly Japan. Dr. Fung then joined Johnson & Johnson (J&J), first as an Executive Director of McNeil Specialty Pharma Division and later as a Compound Development Leader and Vice President in Janssen Oncology. During his tenure at J&J, he was most recognized for his leadership in the development of Imbruvica (Ibrutinib) and Cell Therapy. Before retiring from J&J, he was a Vice President at the J&J Asia-Pacific Innovation Center.
Dr. Fung obtained his B.S. in Pharmacy and M.D. degrees from the University of Utah. He then underwent medical training in Internal Medicine at Johns Hopkins University with additional training in Radiation Oncology at University of Pennsylvania. He later pursued additional education in business and management, earning a Master’s in Health Care Management at Harvard University and an Executive MBA from University of Indianapolis. He has obtained multiple leadership honors and awards during his career from the FDA, Lilly and J&J, and authored/co-authored 60+ publications in many international journals. He is a Fellow of American College of Physicians (FACP) as well as an Adjunct Professor of Peking University.